Activity ID
13292Expires
June 2, 2027Format Type
EnduringCME Credit
1Fee
$150CME Provider: Louisiana Medical Mutual Insurance Company (LAMMICO)
Description of CME Course
The diagnosis of a substance use or opioid use disorder during pregnancy is linked to complications for the mother, fetus, and newborn. Chronically drug exposed fetuses are at high risk for neonatal abstinence syndrome (NAS) or neonatal opioid withdrawal syndrome (NOWS). Anywhere from 45-94% of infants exposed in utero can show signs of withdrawal. From the first hour of life and up to 6 months postpartum, NAS/NOWS may evolve. This activity is part one of a two-part series that explores the evidence-based care of newborns who are at high risk for NAS/NOWS.
ABMS Member Board Approvals by Type
ABMS Lifelong Learning CME Activity
Family Medicine
Commercial Support?
NoNOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
Educational Objectives
a. Adopt universal screening of all pregnant patients.
b. Perform appropriate biologic testing for suspected or known in-utero substance exposure.
Keywords
Withdrawal Syndrome, Opioid Withdrawal, drug exposed fetus, drug exposed newborn
Competencies
Interpersonal & Communication Skills, Medical Knowledge, Patient Care & Procedural Skills, Practice-based Learning & Improvement, Professionalism, Systems-based Practice
CME Credit Type
AMA PRA Category 1 Credit
Practice Setting
Inpatient, Rural, Urban, VA/Military
